BeOne Medicines (ONC) Competitors

BeOne Medicines logo
$403.60 -9.66 (-2.34%)
Closing price 04:00 PM Eastern
Extended Trading
$403.50 -0.10 (-0.02%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ONC vs. PFE, BMY, SNY, GSK, and TAK

Should you buy BeOne Medicines stock or one of its competitors? BeOne Medicines's main competitors and comparable companies include Pfizer (PFE), Bristol Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), and Takeda Pharmaceutical (TAK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BeOne Medicines compare to Pfizer?

Pfizer (NYSE:PFE) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

In the previous week, Pfizer had 41 more articles in the media than BeOne Medicines. MarketBeat recorded 45 mentions for Pfizer and 4 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.95 beat Pfizer's score of 0.37 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pfizer
14 Very Positive mention(s)
7 Positive mention(s)
14 Neutral mention(s)
8 Negative mention(s)
2 Very Negative mention(s)
Neutral
BeOne Medicines
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pfizer has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 0.6% of Pfizer shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pfizer currently has a consensus price target of $30.32, indicating a potential upside of 6.73%. BeOne Medicines has a consensus price target of $440.57, indicating a potential upside of 6.61%. Given Pfizer's higher possible upside, research analysts clearly believe Pfizer is more favorable than BeOne Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer
2 Sell rating(s)
14 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.18
BeOne Medicines
0 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.00

Pfizer has higher revenue and earnings than BeOne Medicines. Pfizer is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$62.58B2.59$7.77B$0.7040.58
BeOne Medicines$5.34B8.49$286.93M$7.8752.51

BeOne Medicines has a net margin of 13.86% compared to Pfizer's net margin of 6.34%. Pfizer's return on equity of 19.88% beat BeOne Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer6.34% 19.88% 8.52%
BeOne Medicines 13.86%19.04%10.70%

Summary

BeOne Medicines beats Pfizer on 11 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Bristol Myers Squibb?

Bristol Myers Squibb (NYSE:BMY) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Bristol Myers Squibb has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Bristol Myers Squibb has a net margin of 18.47% compared to BeOne Medicines' net margin of 13.86%. Bristol Myers Squibb's return on equity of 60.48% beat BeOne Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Bristol Myers Squibb18.47% 60.48% 14.45%
BeOne Medicines 13.86%19.04%10.70%

Bristol Myers Squibb has higher revenue and earnings than BeOne Medicines. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol Myers Squibb$48.19B2.60$7.05B$4.5113.60
BeOne Medicines$5.34B8.49$286.93M$7.8752.51

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bristol Myers Squibb currently has a consensus price target of $65.46, indicating a potential upside of 6.75%. BeOne Medicines has a consensus price target of $440.57, indicating a potential upside of 6.61%. Given Bristol Myers Squibb's higher possible upside, equities analysts clearly believe Bristol Myers Squibb is more favorable than BeOne Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bristol Myers Squibb
1 Sell rating(s)
16 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.47
BeOne Medicines
0 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Bristol Myers Squibb had 34 more articles in the media than BeOne Medicines. MarketBeat recorded 38 mentions for Bristol Myers Squibb and 4 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.95 beat Bristol Myers Squibb's score of 0.36 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bristol Myers Squibb
9 Very Positive mention(s)
7 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral
BeOne Medicines
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Bristol Myers Squibb beats BeOne Medicines on 9 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Sanofi?

Sanofi (NASDAQ:SNY) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Sanofi has higher revenue and earnings than BeOne Medicines. Sanofi is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$49.35B2.34$8.84B$2.0223.53
BeOne Medicines$5.34B8.49$286.93M$7.8752.51

Sanofi currently has a consensus price target of $53.00, indicating a potential upside of 11.51%. BeOne Medicines has a consensus price target of $440.57, indicating a potential upside of 6.61%. Given Sanofi's higher possible upside, equities analysts clearly believe Sanofi is more favorable than BeOne Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
0 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.48
BeOne Medicines
0 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.00

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Sanofi had 3 more articles in the media than BeOne Medicines. MarketBeat recorded 7 mentions for Sanofi and 4 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.95 beat Sanofi's score of 0.64 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BeOne Medicines
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sanofi has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

BeOne Medicines has a net margin of 13.86% compared to Sanofi's net margin of 8.70%. BeOne Medicines' return on equity of 19.04% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Sanofi8.70% 15.16% 8.48%
BeOne Medicines 13.86%19.04%10.70%

Summary

BeOne Medicines beats Sanofi on 12 of the 16 factors compared between the two stocks.

How does BeOne Medicines compare to GSK?

GSK (NYSE:GSK) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

15.7% of GSK shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GSK has higher revenue and earnings than BeOne Medicines. GSK is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK$43.07B2.31$7.54B$2.8817.10
BeOne Medicines$5.34B8.49$286.93M$7.8752.51

In the previous week, GSK had 3 more articles in the media than BeOne Medicines. MarketBeat recorded 7 mentions for GSK and 4 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.95 beat GSK's score of 0.37 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
BeOne Medicines
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

GSK has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

GSK presently has a consensus price target of $56.30, indicating a potential upside of 14.30%. BeOne Medicines has a consensus price target of $440.57, indicating a potential upside of 6.61%. Given GSK's higher possible upside, equities research analysts clearly believe GSK is more favorable than BeOne Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
3 Sell rating(s)
13 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.00
BeOne Medicines
0 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.00

BeOne Medicines has a net margin of 13.86% compared to GSK's net margin of 13.00%. GSK's return on equity of 41.41% beat BeOne Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
GSK13.00% 41.41% 11.09%
BeOne Medicines 13.86%19.04%10.70%

Summary

BeOne Medicines beats GSK on 10 of the 17 factors compared between the two stocks.

How does BeOne Medicines compare to Takeda Pharmaceutical?

BeOne Medicines (NASDAQ:ONC) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, BeOne Medicines and BeOne Medicines both had 4 articles in the media. BeOne Medicines' average media sentiment score of 0.95 beat Takeda Pharmaceutical's score of 0.20 indicating that BeOne Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BeOne Medicines
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Takeda Pharmaceutical
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

BeOne Medicines presently has a consensus target price of $440.57, suggesting a potential upside of 6.61%. Given BeOne Medicines' higher possible upside, equities analysts clearly believe BeOne Medicines is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeOne Medicines
0 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.00
Takeda Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

BeOne Medicines has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market.

BeOne Medicines has higher earnings, but lower revenue than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeOne Medicines$5.34B8.49$286.93M$7.8752.51
Takeda Pharmaceutical$28.32B2.45-$1.01B$0.7628.49

BeOne Medicines has a net margin of 13.86% compared to Takeda Pharmaceutical's net margin of 8.26%. BeOne Medicines' return on equity of 19.04% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
BeOne Medicines13.86% 19.04% 10.70%
Takeda Pharmaceutical 8.26%11.51%5.59%

Summary

BeOne Medicines beats Takeda Pharmaceutical on 13 of the 14 factors compared between the two stocks.

Get BeOne Medicines News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONC vs. The Competition

MetricBeOne MedicinesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$45.37B$13.38B$7.60B$11.72B
Dividend YieldN/A2.58%2.47%4.48%
P/E Ratio50.2127.9733.5830.13
Price / Sales8.296.798.275.60
Price / Cash105.7315.6321.0121.90
Price / Book7.615.394.443.72
Net Income$286.93M$2.88B$3.50B$393.88M
7 Day Performance-3.90%-5.24%-6.53%-6.07%
1 Month Performance9.36%-4.80%-4.93%-7.38%
1 Year Performance10.90%-7.35%-1.73%-7.48%

BeOne Medicines Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONC
BeOne Medicines
3.8787 of 5 stars
$403.60
-2.3%
$440.57
+9.2%
+9.7%$45.37B$5.34B50.2112,000
PFE
Pfizer
2.9751 of 5 stars
$28.80
-0.1%
$30.32
+5.3%
+13.4%$164.18B$62.58B41.1575,000
BMY
Bristol Myers Squibb
4.8072 of 5 stars
$63.31
+1.6%
$65.46
+3.4%
+30.9%$129.48B$48.19B14.0432,500
SNY
Sanofi
4.271 of 5 stars
$48.43
-0.1%
$53.00
+9.4%
-8.2%$117.48B$49.35B23.9974,846
GSK
GSK
4.0918 of 5 stars
$50.55
-0.2%
$56.30
+11.4%
+3.8%$102.28B$43.07B17.5766,841

Related Companies and Tools


This page (NASDAQ:ONC) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners